Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
Eur Rev Med Pharmacol Sci. 2022 Jun;26(11):3799. doi: 10.26355/eurrev_202206_28946.
The article "MiR-466 as a poor prognostic predictor suppresses cell proliferation and EMT in breast cancer cells by targeting PSMA7, by Y. Xiao, S.-J. Zhang, X. Yan, C. Wu, Q.-W. Liu, H.-X. Dong, L.-J. Wang, Y. Hu, published in Eur Rev Med Pharmacol Sci 2021; 25 (18): 5625-5635-DOI: 10.26355/eurrev_202109_26782-PMID: 34604955" has been retracted by the authors as they state that some data cannot be repeated by further experiments. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/26782.
该文“MiR-466 通过靶向 PSMA7 抑制乳腺癌细胞的增殖和 EMT,可作为不良预后预测因子,作者为 Y. Xiao、S.-J. Zhang、X. Yan、C. Wu、Q.-W. Liu、H.-X. Dong、L.-J. Wang、Y. Hu,发表于 2021 年的《欧洲医学与药理学评论》;25(18):5625-5635-DOI: 10.26355/eurrev_202109_26782-PMID: 34604955”已被作者撤回,原因是他们表示一些数据无法通过进一步的实验重复。出版商对由此造成的任何不便表示歉意。https://www.europeanreview.org/article/26782.